| Active substance | Pirtobrutinib |
| Holder | S.A. Eli Lilly N.V. |
| Status | Running |
| Indication | treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 24/11/2023 |